Highly selective N-glucuronidation of four piperazine-containing drugs by UDP-glucuronosyltransferase 2B10

References

• Kaivosaari S, Finel M, Koskinen M. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica. 2011;41:652–669.
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Bock KW, Burchell B, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics. 2005;15:677–685.
   PubMed Web of Science ®Google Scholar
• Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013;45:1121–1132.
   PubMed Web of Science ®Google Scholar
• Hawes EM. N+-glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group. Drug Metab Dispos. 1998;26:830–837.
   PubMed Web of Science ®Google Scholar
• Chen G, Dellinger RW, Gallagher CJ, et al. Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. Pharmacogenet Genomics. 2008;18:181–191.
   PubMed Web of Science ®Google Scholar
• Luo H, Hawes EM, McKay G, et al. N(+)-glucuronidation of aliphatic tertiary amines in human: antidepressant versus antipsychotic drugs. Xenobiotica. 1995;25:291–301.
   PubMed Web of Science ®Google Scholar
• Luo H, Hawes EM, McKay G, et al. N(+)-glucuronidation of aliphatic tertiary amines, a general phenomenon in the metabolism of H1-antihistamines in humans. Xenobiotica. 1991;21:1281–1288.
   PubMed Web of Science ®Google Scholar
• Berg JZ, Mason J, Boettcher AJ, et al. Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype. J Pharmacol Exp Ther. 2010;332:202–209.
   PubMed Web of Science ®Google Scholar
• Fowler S, Kletzl H, Finel M, et al. A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure. J Pharmacol Exp Ther. 2015;352:358–367.
   PubMed Web of Science ®Google Scholar
• Chen G, Dellinger RW, Sun D, et al. Glucuronidation of tobacco-specific nitrosamines by UGT2B10. Drug Metab Dispos. 2008;36:824–830.
   PubMed Web of Science ®Google Scholar
• Kato Y, Izukawa T, Oda S, et al. Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. Drug Metab Dispos. 2013;41:1389–1397.
   PubMed Web of Science ®Google Scholar
• Zhou D, Guo J, Linnenbach AJ, et al. Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine. Drug Metab Dispos. 2010;38:863–870.
   PubMed Web of Science ®Google Scholar
• Chen G, Luo S, Kozlovich S, et al. Association between glucuronidation genotypes and urinary nnal metabolic phenotypes in smokers. Cancer Epidem Biomar. 2016;25:1175–1184.
   PubMed Web of Science ®Google Scholar
• Yuan JM, Koh WP, Murphy SE, et al. Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res. 2009;69:2990–2995.
   PubMed Web of Science ®Google Scholar
• Kaivosaari S, Toivonen P, Hesse LM, et al. Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Mol Pharmacol. 2007;72:761–768.
   PubMed Web of Science ®Google Scholar
• Ghosheh O, Hawes EM. N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases. Drug Metab Dispos. 2002;30:991–996.
   PubMed Web of Science ®Google Scholar
• Erickson-Ridout KK, Zhu J, Lazarus P. Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenet Genomics. 2011;21:539–551.
   PubMed Web of Science ®Google Scholar
• Ghotbi R, Mannheimer B, Aklillu E, et al. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure–an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol. 2010;66:465–474.
   PubMed Web of Science ®Google Scholar
• Court MH. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol. 2005;400:104–116.
   PubMed Web of Science ®Google Scholar
• Lu D, Xie Q, Wu B. N-glucuronidation catalyzed by UGT1A4 and UGT2B10 in human liver microsomes: assay optimization and substrate identification. J Pharm Biomed Anal. 2017;145:692–703.
   PubMed Web of Science ®Google Scholar
• Delbressine LP, Moonen ME, Kaspersen FM, et al. Biotransformation of mianserin in laboratory animals and man. Xenobiotica. 1992;22:227–236.
   PubMed Web of Science ®Google Scholar
• Nishikata M, Nomura A, Iseki K, et al. Enantioselective pharmacokinetics of homochlorcyclizineII: disposition and metabolism of (+)-, (-)- and racemic homochlorcyclizine after oral administration to man. Eur J Clin Pharmacol. 1992;43:533–538.
   PubMed Web of Science ®Google Scholar
• Delbressine LP, Moonen ME, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Investig. 1998;15:45–55.
   PubMed Web of Science ®Google Scholar
• Lu D, Ma Z, Zhang T, et al. Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1. Xenobiotica. 2016;46:1–13.
   PubMed Web of Science ®Google Scholar
• Houston JB, Kenworthy KE. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos. 2000;28:246–254.
   PubMed Web of Science ®Google Scholar
• Kazmi F, Yerino P, Barbara JE, et al. Further characterization of the metabolism of desloratadine and its cytochrome p450 and udp-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 Inhibitor. Drug Metab Dispos. 2015;43:1294–1302.
   PubMed Web of Science ®Google Scholar
• Pattanawongsa A, Nair PC, Rowland A, et al. Human UDP-Glucuronosyltransferase (UGT) 2B10: validation of cotinine as a selective probe substrate, inhibition by UGT enzyme-selective inhibitors and antidepressant and antipsychotic drugs, and structural determinants of enzyme inhibition. Drug Metab Dispos. 2016;44:378–388.
   PubMed Web of Science ®Google Scholar
• Koyama E, Chiba K, Tani M, et al. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996;278:21–30.
   PubMed Web of Science ®Google Scholar
• Stormer E, Von Moltke LL, Shader RI, et al. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000;28:1168–1175.
   PubMed Web of Science ®Google Scholar
• Vella-Brincat JW, Begg EJ, Jensen BP, et al. The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients. J Pain Symptom Manage. 2012;43:540–548.
   PubMed Web of Science ®Google Scholar
• Chen G, Blevins-Primeau AS, Dellinger RW, et al. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism. Cancer Res. 2007;67:9024–9029.
   PubMed Web of Science ®Google Scholar
• Kerdpin O, Mackenzie PI, Bowalgaha K, et al. Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab Dispos. 2009;37:1948–1955.
   PubMed Web of Science ®Google Scholar
• Green MD, Bishop WP, Tephly TR. Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Dispos. 1995;23:299–302.
   PubMed Web of Science ®Google Scholar
• Argikar UA, Remmel RP. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009;37:229–236.
   PubMed Web of Science ®Google Scholar
• Zhou J, Tracy TS, Remmel RP. Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos. 2010;38:431–440.
   PubMed Web of Science ®Google Scholar
• Jin CJ, Miners JO, Lillywhite KJ, et al. cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem Biophys Res Commun. 1993;194:496–503.
   PubMed Web of Science ®Google Scholar
• Breyer-Pfaff U, Fischer D, Winne D. Biphasic kinetics of quaternary ammonium glucuronide formation from amitriptyline and diphenhydramine in human liver microsomes. Drug Metab Dispos. 1997;25:340–345.
   PubMed Web of Science ®Google Scholar
• Kaivosaari S, Toivonen P, Aitio O, et al. Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes. Drug Metab Dispos. 2008;36:1529–1537.
   PubMed Web of Science ®Google Scholar
• Margaillan G, Rouleau M, Klein K, et al. Multiplexed targeted quantitative proteomics predicts hepatic glucuronidation potential. Drug Metab Dispos. 2015;43:1331–1335.
   PubMed Web of Science ®Google Scholar
• Izukawa T, Nakajima M, Fujiwara R, et al. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos. 2009;37:1759–1768.
   PubMed Web of Science ®Google Scholar
• Fallon JK, Neubert H, Hyland R, et al. Targeted quantitative proteomics for the analysis of 14 UGT1As and −2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. J Proteome Res. 2013;12:4402–4413.
   PubMed Web of Science ®Google Scholar
• Lu D, Wang S, Xie Q, et al. Transcriptional regulation of human UDP-Glucuronosyltransferase 2B10 by farnesoid X receptor in human hepatoma HepG2 cells. Mol Pharm. 2017;14:2899–2907.
   PubMedGoogle Scholar
• Dluzen DF, Sutliff AK, Chen G, et al. Regulation of UGT2B expression and activity by miR-216b-5p in liver cancer cell lines. J Pharmacol Exp Ther. 2016;359:182–193.
   PubMed Web of Science ®Google Scholar
• Wassenaar CA, Conti DV, Das S, et al. UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers. Cancer Epidem Biomar. 2015;24:94–104.
   PubMed Web of Science ®Google Scholar
• Labriet A, Allain EP, Rouleau M, et al. Posttranscriptional regulation of UGT2B10 hepatic expression and activity by alternative splicing. Drug Metab Dispos. 2018;
   PubMed Web of Science ®Google Scholar
• Chiu SH, Huskey SW. Species differences in N-glucuronidation. Drug Metab Dispos. 1998;26:838–847.
   PubMed Web of Science ®Google Scholar